European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Stratification of Obesity Phenotypes to Optimize Future Therapy

Descrizione del progetto

Ottimizzare il trattamento dell’obesità tramite una suddivisione in gruppi pertinenti

L’obesità è spesso percepita come una mancanza di autocontrollo piuttosto che come una malattia. Il progetto SOPHIA, finanziato dall’UE, mira a sfidare quest’idea sbagliata fornendo prove dell’eterogeneità della malattia, e a creare un valore condiviso in cui tutte le parti coinvolte possano ottenere buoni risultati facendo del bene. I ricercatori individueranno indicatori dei rischi delle complicanze dell’obesità e le sottopopolazioni a rischio di specifiche complicanze (come diabete di tipo 2 (T2D), malattie cardiovascolari, cancro e artrosi). Il progetto individuerà inoltre indicatori di risposta a diversi trattamenti per l’obesità. I risultati di questa ricerca consentiranno ai pazienti di ricevere informazioni di qualità migliore il che a sua volta darà loro gli strumenti necessari per prendere decisioni relative al loro trattamento insieme agli operatori sanitari.

Obiettivo

SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulations in terms of (a) the risks of complications linked to obesity, (b) response to various obesity treatments. The subpopulations will be characterised in terms of operational variables (phenotypic, genetic, behavioural, environmental, and omics). These predictive variables will facilitate diagnosis and underpin personalised and protocolised obesity care.
Patient priorities regarding risk and response will influence all aspects of our work. SOPHIA will create a federated database of premier EU cohorts to identify operational variables that are predictive of risk and treatment response in people with and without diabetes. We will validate the predictive value of these variables before creating clinically-useful algorithms to decide “when-to-treat” and “how-to-treat”. Biomarker variables will feed into innovative assays, tests and research targets. We will interpret and analyse our results, to identify shared value across all stakeholders (patients, clinicians, industry, payers).
SOPHIA will change attitudes and experience of obesity by (1) demonstrating the heterogeneity of the disease, (2) identifying people at risk of complications, (3) identifying the best treatment for each individual, (4) delivering a common vocabulary and shared understanding of obesity, (5) demonstrating shared value, which combines commercial opportunity with societal benefit.
Our ambition will only be realised if (a) payers agree to fund treatment, (b) industry generate effective treatments, (c) clinicians are prepared to prescribe treatments, and (d) patients are prepared to take treatments. The evidence base does not currently exist. SOPHIA will deliver this evidence and the shared value analysis to drive this revolution in obesity care.

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Contribution nette de l'UE
€ 1 611 729,00
Indirizzo
BELFIELD
4 Dublin
Irlanda

Mostra sulla mappa

Regione
Ireland Eastern and Midland Dublin
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 801 729,00

Partecipanti (38)